2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

322. Hemophilia A and B: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Gene Therapy, Women’s Health, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Hemophilia, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

3044 GLP-1 receptor agonist and survival, bleeding, and thrombotic outcomes in adults with hereditary hemophilia and von Willebrand disease: A propensity-matched retrospective cohort study

Colton Jones, MD, Hematology, Oncologyfellow, Vanessa Velazquez, MD2, Jacob Schmelz, MD3, Usha S Perepu, MD4
1 University of Texas Health Science Center San Antonio, San Antonio, United States
2 University of Texas Health Science Center San Antonio, San Antonio, United States
3 University of Texas Health Science Center San Antonio, San Antonio, United States
4 University of Texas Health Science Center San Antonio, San Antonio, United States
Introduction
GLP-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes (T2DM) and obesity, and both conditions are rising in prevalence among people with inherited bleeding disorders. Beyond metabolic effects, GLP-1 RAs modulate hemostasis: GLP-1 receptors are expressed on platelets and megakaryocytes, and receptor activation attenuates platelet aggregation. Clinical data are conflicting, as meta-analyses of randomized trials report both reduced venous thromboembolism (VTE) risk and no association. Because patients with inherited bleeding disorders are systematically excluded from these trials, the net bleeding and thrombotic effect of GLP-1 RAs in the setting of a baseline hemostatic defect remains unknown. This study is the first to evaluate survival, bleeding, and thrombotic risk with GLP-1 RA therapy in patients with hereditary hemophilia and Von Willebrand disease (vWD).
Methods
Using the TriNetX Global Federated Network (>140 million patients, 114 healthcare organizations), we identified adults with hereditary vWD or factor VIII, IX, or XI deficiency diagnosed January 2015–January 2025. Cohort A initiated a GLP-1 RA after diagnoses of obesity or diabetes and hereditary vWD or factor VIII, IX, or XI deficiency (index = first prescription). Cohort B comprised never-users assigned an equivalent index date. Patients with hereditary or acquired thrombophilia, or the outcome of interest before the index date, were excluded. Propensity score matching balanced demographics, comorbidities, hemoglobin, BMI, HbA1c, malignancy, and pregnancy status. The primary endpoint was overall survival (OS); secondary endpoints were bleeding and thrombotic events. Time-to-event outcomes were analyzed with Cox proportional hazards models, reported as hazard ratios (HR) with 95% CI.
Results:
After matching, 6,560 patients were analyzed (n=3,280 per cohort); median follow-up was 1,300 days. Mean age was 44.8 years (GLP-1 RA) and 46.2 years (control); both cohorts were 77% female and 77% White (10.4% vs 9.0% Black; 9% vs 10% Hispanic/Latino). Residual imbalances persisted in hemoglobin (13.0 vs 12.6 g/dL) and HbA1c (6.3% vs 5.8%) and were retained as covariates in the Cox models. GLP-1 RA exposure was associated with improved overall survival (47/3,201 vs 193/3,216 deaths; HR 0.20, 95% CI 0.15–0.27; p<0.001). No significant association was observed with any thrombotic or bleeding endpoint: VTE (HR 1.17, 0.85–1.61), myocardial infarction (HR 0.88, 0.61–1.27), cerebrovascular accident (HR 1.04, 0.71–1.51), transient ischemic attack (HR 1.19, 0.71–1.98), hemarthrosis (HR 1.59, 0.84–3.04), non-traumatic intracranial hemorrhage (HR 0.86, 0.45–1.64), hematoma (HR 0.52, 0.25–1.11), and gastrointestinal bleeding (HR 1.22, 0.98–1.53).
Conclusion:
In the largest cohort to date evaluating GLP-1RA in adults with hereditary hemophilia or vWD, GLP-1 RA exposure was associated with an 80% improvement in OS with no excess bleeding or thrombotic risk. These null bleeding associations, though hypothesis-generating, provide the first population-level associations that GLP-1 RA is not associated with an amplification in hemorrhagic risk in patients with a baseline hemostatic defect, despite the documented antiplatelet effects of this drug class. The absence of any thrombotic signal further supports hemostatic neutrality in this population. Given the rising prevalence of obesity and type 2 diabetes among people with inherited bleeding disorders, and their systematic exclusion from GLP-1 RA randomized trials, this data addresses a clinically urgent evidence gap. Prospective registry-based studies incorporating disease severity, inhibitor status, and treatment regimens are warranted.
Colton Jones, MD, Hematology, Oncologyfellow: No relevant conflicts of interest to declare.